Cargando…
Data exclusivity through New Drug Reexamination in Korea: sibutramine hydrochloride (Reductil®) vs. sibutramine mesylate (Slimmer®) as an example
The ‘equivalent-or-more-but-not-the-same-data’ provision in the Regulation on the Safety and Efficacy Evaluation of New Drug in Korea has served as the de facto data exclusivity term for any drug identical to a product subject to new drug reexamination. The legal debate that occurred between Abbott...
Autor principal: | Lee, Howard |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean Society for Clinical Pharmacology and Therapeutics
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6989260/ https://www.ncbi.nlm.nih.gov/pubmed/32055548 http://dx.doi.org/10.12793/tcp.2018.26.2.49 |
Ejemplares similares
-
Sibutramine (Reductil®)-Induced Cutaneous Leukocytoclastic Vasculitis: A Case Report
por: Ha, You Jin, et al.
Publicado: (2011) -
Slimmer or Fertile? Pharmacological Mechanisms Involved in Reduced Sperm Quality and Fertility in Rats Exposed to the Anorexigen Sibutramine
por: Borges, Cibele S., et al.
Publicado: (2013) -
Sibutramine on Cardiovascular Outcome
por: Scheen, André J.
Publicado: (2011) -
Phentermine, Sibutramine and Affective Disorders
por: An, Hoyoung, et al.
Publicado: (2013) -
Cardiovascular Safety Pharmacology of Sibutramine
por: Yun, Jaesuk, et al.
Publicado: (2015)